Multimedia

Multimedia

Podcasts and video interviews with researchers, commentators, and experts in the field

video

ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients

Mark J. Levis, MD, PhD, discusses the results of a phase I/II trial of ASP2215, which was shown to potently, selectively, and sustainably inhibit...

Kenneth Ataga, MD: Crizanlizumab: A New Option for Managing Sickle Cell-Related Pain Crises?

The first-in-class humanized monoclonal antibody crizanlizumab reduced the rate of sickle cell-related pain crises, compared with placebo. Dr. Ataga discusses results of the SUSTAIN...
video

Sherrill J. Schlicter, MD: Prolonging Platelet Shelf-Life With DMSO

Transfusion with cryopreserved platelets may offer superior bleeding control for thrombocytopenic patients. Dr. Schlicter shares results from a phase I study, and gives a...
video

Steven Pipe, MD: Changing the Delivery of Bleeding Prevention for Hemophilia Patients

Dr. Pipe, a speaker in the Special Education Session on Newly Approved Drugs, reviews what clinicians need to know about coagulation factor IX (recombinant)/antihemophilic...
video

Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML

Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.
video

Crystal Mackall, MD: Passing the Checkpoint With New Approaches to Immunotherapy

Checkpoint blockade is revolutionizing immunotherapy, but there is room for improvement. Dr. Mackall, who chaired a session on “Novel Approaches to Immunotherapy,” speaks about...
video

Graham Jackson, MD: Lenalidomide Maintenance Is Effective in All Types of Myeloma Patients

Dr. Jackson shares results from the phase III Myeloma XI study, which compared patients treated with lenalidomide maintenance therapy or no maintenance therapy in...
video

Adam D. Cohen, MD: Expanding CAR T Cells to Treat Myeloma

Dr. Cohen talks about the potential for bringing CAR T-cell therapy to heavily-pretreated myeloma patients, as well as the potential toxicities.
video

Ruxolitinib in CMML: Study Shows Promising Results

Eric Padron, MD, shares results from the phase I study of ruxolitinib in chronic myelomonocytic leukemia, a rare type of myelodysplastic, myeloproliferative neoplasm with...
video

COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis

Ruben A. Mesa, MD, provides an update on the COMFORT-1 trial, which found that ruxolitinib has durable efficacy and long-term safety in patients with...
Advertisement

Current Issue

May 2017, Volume 3, Issue 6

This issue discusses the legacy of Agent Orange and hematologic malignancies, a debate over transplant in myelodysplastic syndromes, and more.